利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.05 秒)

    4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
    9.
    发明授权
    4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines 失效
    4-氨基取代-2-取代-1,2,3,4-四氢喹啉

    公开(公告)号：US06489478B1

    公开(公告)日：2002-12-03

    申请号：US09671221

    申请日：2000-09-27

    申请人： Michael P. DeNinno ,  George T. Magnus-Aryitey ,  Roger B. Ruggeri ,  Ronald T. Wester

    发明人： Michael P. DeNinno ,  George T. Magnus-Aryitey ,  Roger B. Ruggeri ,  Ronald T. Wester

    IPC分类号： A61K3147

    CPC分类号： C07D413/12 ,  C07D215/42 ,  C07D215/46 ,  C07D221/16 ,  C07D417/12

    摘要： Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

    摘要翻译： 胆固醇酯转移蛋白抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于提高某些血浆脂质水平（包括高密度脂蛋白胆固醇）并降低某些其他血浆脂质水平的用途，例如LDL-胆固醇和甘油三酯，并因此治疗 HDL胆固醇水平升高和/或LDL-胆固醇和甘油三酯水平升高的疾病，如一些哺乳动物，包括人类的动脉粥样硬化和心血管疾病。

    CETP inhibitors in combination with antihypertensive agents and uses thereof
    10.
    发明授权
    CETP inhibitors in combination with antihypertensive agents and uses thereof 失效

    公开(公告)号：US07071210B2

    公开(公告)日：2006-07-04

    申请号：US10459026

    申请日：2003-06-10

    申请人： Roger B. Ruggeri

    发明人： Roger B. Ruggeri

    IPC分类号： C07D215/38 ,  A61K31/47

    CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/47 ,  A61K2300/00

    摘要： This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetaliproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female).